Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma

BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hobeika, Liliane, Self, Sally E, Velez, Juan Carlos Q
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190298/
https://www.ncbi.nlm.nih.gov/pubmed/25267524
http://dx.doi.org/10.1186/1471-2369-15-156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190298/
https://www.ncbi.nlm.nih.gov/pubmed/25267524
http://dx.doi.org/10.1186/1471-2369-15-156

Ejemplares similares